msnbc.comEverolimus, exemestane improved outcomes in HT-resistant breast cancerHemOncTodayCombining everolimus and exemestane improved PFS among postmenopausal women with advanced breast cancer resistant to hormonal therapy, according to data from a ph…

Proactive Investors USA & CanadaAfinitor Study Meets Primary EndpointDrug Discovery & DevelopmentA Phase 3 study of Novartis' Afinitor (everolimus) tabletsin patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sc…